araag2/HINT huggingface dataset:
Clinical trial NCT00291330 (phase 3, status: completed)
Conditions: thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: dabigatran etexilate 150 mg, warfarin (inr 2-3)
SMILES: CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion criteria

          1. Acute deep vein thrombosis (DVT) of the leg involving proximal veins, and/or pulmonary
             embolism (PE) iin patients for whom at least 6 months of anticoagulant therapy is
             considered appropriate

          2. Male or female, being 18 years of age or older

          3. Written informed consent for study participation

        Exclusion criteria

          1. Overt symptoms of VTE for longer than 2 weeks prior to enrolment

          2. PE satisfying at least one of the following criteria: Haemodynamic instability,
             embolectomy is indicated or performed, thrombolytic therapy is indicated or performed,
             or suspected source of PE is other than the legs

          3. Actual or anticipated use of vena cava filter

          4. Contraindications to anticoagulant therapy

          5. Patients who in the investigators opinion should not be treated with warfarin

          6. Allergy to heparins or other alternate approved therapy used for initial treatment,
             warfarin or dabigatran, or to one of the excipients included in these medications

          7. Patients who in the investigators judgement are perceived as having an excessive risk
             of bleeding

          8. Known anaemia

          9. Need of anticoagulant treatment for disorders other than VTE

         10. Recent unstable cardiovascular disease

         11. Elevated AST or ALT > 2x ULN

         12. Liver disease expected to have any potential impact on survival

         13. Patients who have developed transaminase elevations upon exposure to ximelagatran

         14. Severe renal impairment

         15. Women who are pregnant, nursing, or of childbearing potential who refuse to use a
             medically acceptable form of contraception

         16. Participation in another clinical trial with an investigational drug during the last
             30 days or previous participation in this study

         17. Patients considered unsuitable for inclusion by the investigator
Clinical trial NCT01360645 (phase 3, status: completed)
Conditions: depressive disorder, depression, depressive disorder, major, mood disorders, mental disorders
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F32.A, F53.0, P91.4, Z13.31, Z13.32, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F34.81, F39, F34.9, F43.21, F10.14, F10.24, F11.14, F48.9, F99, F51.05, F51.13, F09, F06.8, F48.8
Drugs: opc-34712 + adt, placebo + adt, placebo + adt
SMILES: O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects between 18 and 65 years of age, with diagnosis of major
             depressive disorder, as defined by DSM-IV-TR criteria

          -  The current depressive episode must be equal to or greater than 8 weeks in duration

          -  Subjects must report a history for the current depressive episode of an inadequate
             response to no more than three adequate antidepressant treatments

        Exclusion Criteria:

          -  Females who are breast-feeding and/or who have a positive pregnancy test result prior
             to receiving study drug

          -  Subjects who report an inadequate response to more than three adequate trials of
             antidepressant treatments during current depressive episode at a therapeutic dose for
             an adequate duration.

          -  Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic
             or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other
             psychotic disorder, Bipolar I or II disorder

          -  Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of
             borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality
             disorder
Clinical trial NCT00597753 (phase 3, status: completed)
Conditions: chronic renal failure, chronic kidney disease, anemia
ICD codes: I13.11, I13.2, I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: peginesatide, epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria

          1. Participants with chronic renal failure on hemodialysis for ≥ 3 months prior to
             randomization.

          2. On intravenous epoetin alfa maintenance therapy continuously prescribed for a minimum
             of 8 weeks prior to randomization.

          3. Four consecutive hemoglobin values with a mean ≥ 10.0 and ≤ 12.0 g/dL during the
             screening period

        Exclusion Criteria

          1. Females who are pregnant or breast-feeding.

          2. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule
             or to all parenteral iron supplementation products.

          3. Known bleeding or coagulation disorder.

          4. Known hematologic disease or cause of anemia other than renal disease

          5. Poorly controlled hypertension

          6. Evidence of active malignancy within one year prior to randomization.

          7. Temporary (untunneled) dialysis access catheter.

          8. A scheduled kidney transplant

          9. A scheduled surgery that may be expected to lead to significant blood loss.
Clinical trial NCT00474370 (phase 3, status: completed)
Conditions: hiv infections, acquired immunodeficiency syndrome
ICD codes: Z21, D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: vicriviroc, placebo
SMILES: COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must be infected with HIV-1 virus.

          -  Subject must have documented plasma HIV-1 RNA >1000 copies/mL within 60 days of Visit
             1/Day 1 (randomization) and must be either

               -  on a stable regimen of 3 or more antiretrovirals (ART) for at least 4

        weeks prior to the screening visit

        OR

          -  on no ART agents for at least 4 weeks prior to

        the screening visit.

          -  Subject must be ART experienced and have documented resistance to at least 2 of the
             following 3 drug classes: nucleoside reverse transcriptase inhibitor (NRTI);
             non-nucleoside reverse transcriptase inhibitor (NNRTI); or protease inhibitor (PI)

        OR

        Subject must have ART class experience for at least 6 months with at least two of the
        following: one NRTI; one NNRTI; two PIs (excluding low-dose ritonavir).

          -  Women of child-bearing potential must agree to use a medically accepted method of
             contraceptive as defined by the protocol.

          -  Subject must be willing to initiate CD4+ cell count-guided chemoprophylaxis to prevent
             opportunistic infection as defined in protocol.

        Exclusion Criteria:

          -  Subjects with detectable CXCR4-tropic or dual/mixed CCR5/CXCR4-tropic HIV isolates at
             Screening.

          -  Subjects with prior history of malignancy (with exceptions of cutaneous Kaposi's
             sarcoma without visceral or mucosal involvement that resolved with HAART but without
             systemic anti-cancer treatment, and basal-cell carcinoma of skin); or prior receipt of
             cytotoxic cancer chemotherapy that may increase the risk of malignancy.

          -  Subjects with seizure disorder requiring anti-seizure therapy or with any condition
             that is likely to increase risk of seizure (CNS malignancy or toxoplasmosis).
Clinical trial NCT00207766 (phase 3, status: completed)
Conditions: crohn disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: infliximab or placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Single or multiple draining fistulas

          -  Crohn's disease of at least 3 months' duration,

        Exclusion Criteria:

          -  Crohn's disease complications for which surgery might be indicated

          -  Positive stool culture
Clinical trial NCT00136370 (phase 3, status: unknown status)
Conditions: infant, newborn, diseases, sepsis, puerperal infection
ICD codes: A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7
Drugs: chlorhexidine
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Pregnant

          -  Plan to deliver at Chris Hani Baragwanath Hospital or one of its satellite clinics

          -  Plan to remain in Soweto for at least two months after delivery

          -  Are able to understand and give informed consent

          -  Are at least 15 years old at time of registration

        Exclusion Criteria:

          -  Planned delivery by caesarean section

          -  Antenatal ultrasound revealing major fetal congenital anomalies

          -  Have known or suspected condition in which vaginal exams are contraindicated, e.g.
             placenta previa

          -  Have a history of allergic reaction to any topical antiseptic solution

          -  Present to labour ward with infant born before arrival

          -  Present to labour ward with significant vaginal bleeding during labour

          -  Present with known intrauterine fetal death prior to randomization

          -  Subject noted to be in full cervical dilatation or have baby's head on perineum

          -  Infant noted to be in face presentation on first vaginal examination

          -  Noted to have genital ulcers present on first vaginal examination
Clinical trial NCT00265343 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Continue to meet all demographic and procedural

        inclusion criteria of the 25543 trial (NCT 00212836; P05817) to enter into

        this extension trial.

          -  Have demonstrated an acceptable

        degree of compliance and completed the 25543

        trial, and would benefit from continued treatment

        according to the investigator.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable clinically significant

        medical condition.

          -  Have been judged to be medically

        noncompliant in the management of their disease.
Clinical trial NCT00721955 (phase 3, status: completed)
Conditions: bipolar i disorder
ICD codes: F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76
Drugs: inhaled placebo, inhaled loxapine 5 mg, inhaled loxapine 10 mg
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2, CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adult patients with bipolar 1 disorder and acute agitation

        Exclusion Criteria:

          -  Agitation caused primarily by acute intoxication

          -  History of drug or alcohol dependence

          -  Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug
             administration
Clinical trial NCT00225199 (phase 3, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: visanne (bay86-5258, sh t00660aa), placebo
SMILES: [H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients with endometriosis-associated pelvic pain

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  history or suspicion of hormone dependent tumor

          -  therapy resistant endometriosis

          -  need for primary surgical treatment

          -  any other conditions which forbid the participation.
Clinical trial NCT00668850 (phase 3, status: unknown status)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: generex oral-lyn™, regular human insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be male or female between the ages 18 to 75 years

          -  Type 1 diabetes mellitus patients (according to ADA and/or WHO classification) who
             have >1 year history of type 1 DM and are currently managed with daily insulin
             injections totalling 0.3 to 0.8 IU/kg of body weight;

          -  Current physical examination, vital signs and ECG at screening that reveals no
             clinically significant abnormalities;

          -  Have a body mass index (BMI) <27;

          -  8.5% (inclusively)<Have a glycosylated haemoglobulin HbA1c

          -  Willing and able to follow the American Diabetes Association diet guidelines for type
             1 diabetes; be able to commit to perform home blood glucose monitoring and record
             values as well as hypoglycemic events

          -  Willing to give written informed consent prior to admission into the study.

        Exclusion Criteria:

          -  Have a significant active asthma or suspected abnormalities of buccal mucosa;
             cardiovascular, cerebrovascular, hepatic, renal, gastrointestinal, hematological, or
             auto-immune disease (other than auto-immune thyroid disease); history of athopy or
             drugs allergy

          -  Have evidence of unstable retinopathy (defined as pre-proliferative or proliferative
             retinopathy currently requiring photocoagulation therapy), nephropathy or neuropathy
             (gastroparesis or orthostatic hypotension);

          -  Have hypoglycemia unawareness;

          -  Have had more than one episode of severe hypoglycemia with seizure or coma or
             ketoacidosis within the past 12 months;

          -  Have a blood pressure in excess of 160/100 mmHg at the Screening visit;

          -  Have had any acute illness within the 2 weeks prior to screening;

          -  Have a history of drug or alcohol abuse that in the opinion of the Investigator would
             interfere with participation in the protocol
Clinical trial NCT00709904 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: open-label semuloparin sodium, placebo (for semuloparin sodium), semuloparin sodium
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, \N
Eligibility criteria:

        Inclusion Criteria:

          -  In the run-in phase:

               -  Standard surgery for fracture of the upper third of the femur, including femoral
                  head and neck

          -  In the double-blind phase following the run-in phase:

               -  Completion of the run-in phase without permanent treatment discontinuation

        Exclusion Criteria:

          -  Any major orthopedic surgery within 3 months prior to enrolment;

          -  Deep vein thrombosis or pulmonary embolism within the last 12 months, or known
             post-phlebitic syndrome;

          -  High risk of bleeding;

          -  Known hypersensitivity to heparins;

          -  Any contraindication to the performance of venography;

          -  End stage renal disease or patient on dialysis

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00046384 (phase 3, status: completed)
Conditions: bipolar i disorder
ICD codes: F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Patients with acute symptoms of Bipolar Disorder
Clinical trial NCT00327587 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan + amlodipine, valsartan + hctz, amlodipine + hctz, valsartan + amlodipine + hctz
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of moderate to severe hypertension (MSDBP ≥ 100 mmHg and < 120 mmHg, MSSBP ≥
             145 mmHg and < 200 mmHg).

        Exclusion Criteria:

          -  Patients on two or more antihypertensive drugs with MSSBP ≥ 180 mmHg and/or MSDBP ≥
             110 mmHg at Visit 1.

          -  Patients on three or more antihypertensive drugs with MSDBP ≥ 90 mmHg and < 110 mmHg,
             and/or MSSBP ≥ 140 mmHg and < 180 mmHg at Visit 1.

          -  Patients on four or more antihypertensive drugs at Visit 1.

          -  Arm circumference > 42 cm for patients participating in ABPM.

        Other protocol-defined exclusion criteria may apply.
Clinical trial NCT00546637 (phase 3, status: completed)
Conditions: overactive bladder syndrome
ICD codes: N32.81
Drugs: fesoterodine, placebo
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men aged 40 years and above.

          -  On a stable and well-tolerated dose of an alpha-blocker prescribed for LUTS for at
             least 6 weeks prior to screening (Visit 1).

          -  Persistent symptoms of OAB with urinary frequency >=8 times/24 hours and
             micturition-related urgency episodes >=3 episode/24 hours.

        Exclusion Criteria:

          -  Contraindication to fesoterodine (antimuscarinics).

          -  Previous history of acute urinary retention requiring catheterization or severe
             voiding difficulties in the judgment of the investigator, prior to baseline.

          -  Unable to follow the study procedures, including completion of self-administered
             bladder diary and patient reported outcome questionnaires.
Clinical trial NCT01100203 (phase 3, status: terminated)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: eplerenone
SMILES: [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Reason stopped: 
    it was not possible within the time frame to recruit the planned no. of patients.
  
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 years age ≤ 80 years age

          -  voluntarily signed informed consent

          -  15 ml/min/1,73 m2 ≤ estimated Glomerular Filtration Rate < 60 ml/min/1,73 m2

          -  BP ≥ 130/80 mmHg or undergoing anti-hypertensive treatment

        Exclusion Criteria:

          -  p-potassium is > 5.0 mM

          -  allergy to contents

          -  treated with spironolactone

          -  treated with potent inhibitors of CYP3A4 (see SPC for details)

          -  treated with lithium, ciclosporin, tacrolimus, prednisolone, or other
             immunosuppressing drug

          -  inborn errors of metabolism (see SPC for details)

          -  pregnancy or lactation

          -  fertile woman, not using safe contraception devices

          -  dementia or other psychiatric disorder, making understanding of the study conditions
             impossible

          -  other severe, chronic illness besides CKD, including liver insufficiency, according to
             investigators' judgement

          -  vascular surgery including stenting or graft implantation on a. brachialis, aorta or
             the carotid arteries

          -  systolic BP > 200 mmHg

          -  immeasurable pulse amplitude
Clinical trial NCT00119119 (phase 3, status: terminated)
Conditions: hepatitis c, chronic, liver fibrosis
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, K71.7, K70.2
Drugs: pentoxyphilline, tocopherol
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C
Eligibility criteria:

        Inclusion Criteria:

          -  Age between 18 and 75 years

          -  Chronic hepatitis C defined by positive HCV Ab and HCV RNA and histological proven
             injuries

          -  Liver biopsy with a size over or equal to 15mm, performed within 3 years of enrolment,
             with a Metavir score of activity from 0 to 2 and fibrosis score of 2 or 3.

          -  Non long term responders or patients with contra-indication or intolerance to
             interferon alfa or ribavirin

          -  No anti-viral treatment during the trial

          -  Signed written informed consent

        Exclusion Criteria:

          -  Alcohol consumption over or equal to 40 g/d

          -  Allergy to tocopherol or pentoxyphilline

          -  Treatment with platelet anti-aggregates, anti-vitamin K, theophylline, armophylline

          -  Treatment with tocopherol or pentoxyphilline since the last liver biopsy

          -  Pregnancy, breast feeding, lack of contraception

          -  Decompensated cirrhosis, organ graft, chronic renal insufficiency

          -  BMI over 27

          -  Diabetes type I or II

          -  Other etiology of liver disease (HBV, HIV, hemochromatosis, alfa-1 antitrypsin
             deficiency, Wilson's disease, auto-immune hepatitis, drug-related hepatitis)